Consolidated Entities and Acquisitions - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands		3 Months Ended						9 Months Ended		12 Months Ended
	Jul. 20, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income statements
Total revenue		$ 67,259			$ 67,257			$ 224,623	$ 265,536
Other income, net		1,047			28			(4,289)	(750)
Income tax expense, net		3,906			57,077			14,706	63,061
Net income (loss)		82,046	$ 1,280	$ 34,865	229,347	$ 21,371	$ 37,858	118,191	288,576
Royalty revenue
Income statements
Total revenue		$ 53,558			62,150			$ 172,681	260,429
Theravance Respiratory Company, LLC
CONSOLIDATED ENTITIES
Ownership interest in LLC										15.00%
Proceeds from sale of economic interest under Equity Purchase Agreement	$ 277,500
Contingent sales based milestone payment	50,000
Cash distribution	4,400
Equity method investments	$ 39,400
Income statements
Operating expenses					(5)				332
Income (loss) from operations					5				71,697
Other income, net					0				10
Realized loss					(39,386)				(39,386)
Income tax expense, net					0				1
Changes in fair values of equity and long-term investments					0				(8,884)
Net income (loss)					39,381				23,438
Theravance Respiratory Company, LLC | Royalty revenue
Income statements
Total revenue					$ 0				$ 72,029